To present the most updated American College of Radiology consensus guidelines formed from an expert panel on treatment of locally advanced, high-risk prostate cancer METHODS:: The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer-reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The panel summarized the most recent and relevant literature on the topic and voted on 4 clinical variants illustrating the appropriate management of locally advanced, high-risk cancer. Numerical rating and commentary reflecting the panel consensus was given for each treatment approach in each variant.
Aggressive local approaches including surgery followed by adjuvant XRT, beam combined with androgen deprivation therapy, and beam combined with brachytherapy have resulted in unpresented success in locally advanced, high-risk prostate cancer. By combining most recent medical literature and expert opinion, this guideline can aid clinicians in the appropriate integration of available therapeutic modalities.
American journal of clinical oncology. 2017 Jan 04 [Epub ahead of print]
Patrick W McLaughlin, Adam L Liss, Paul L Nguyen, Dean G Assimos, Anthony V D'Amico, Alexander R Gottschalk, Gary S Gustafson, Sameer R Keole, Stanley L Liauw, Shane Lloyd, Benjamin Movsas, Bradley R Prestidge, Timothy N Showalter, Al V Taira, Neha Vapiwala, Brian J Davis, Expert Panel on Radiation OncologyProstate
*University of Michigan, Novi ∥William Beaumont Hospital, Troy ††Henry Ford Health System, Detroit, MI †Dana-Farber Cancer Institute/Brigham and Women's Hospital, American Society of Clinical Oncology, Boston, MA ‡University of Alabama School of Medicine, Birmingham, AL, American Urological Association §University of California San Francisco, San Francisco ∥∥Mills Peninsula Hospital, San Mateo, CA ¶Mayo Clinic, Scottsdale, AZ #The University of Chicago Medical Center, Chicago, IL **Huntsman Cancer Hospital, Salt Lake City, UT ‡‡Bon Secours Cancer Institute, Norfolk §§University of Virginia, Charlottesville, VA ¶¶University of Pennsylvania, Philadelphia, PA ##Mayo Clinic, Rochester, MN.